Lisa von Moltke - Apr 15, 2025 Form 4 Insider Report for Zenas BioPharma, Inc. (ZBIO)

Role
Head of Research and Development and Chief Medical Officer
Signature
By: /s/ Chase Jayasekera, Attorney-in-Fact
Stock symbol
ZBIO
Transactions as of
Apr 15, 2025
Transactions value $
$0
Form type
4
Date filed
4/17/2025, 04:01 PM
Previous filing
Mar 21, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZBIO Stock Option (Right to Buy) Award $0 +400K $0.00 400K Apr 15, 2025 Common Stock 400K $8.72 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 25% of the underlying shares of common stock on March 17, 2025, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal month installments over 36 months thereafter, subject to continued service.

Remarks:

Head of Research and Development and Chief Medical Officer